119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands

Hoogendijk, Jessica E.; Amato, Anthony A.; Lecky, Bryan; Choy, Ernest; Lundberg, Ingrid E.; Rose, Michael R.; Vencovský, Jiří; Visser, Marjolein; Hughes, Richard

doi:10.1016/j.nmd.2004.02.006

Cited by 792 publications

(702 citation statements)

References 42 publications

Supporting

Mentioning

636

Contrasting

Unclassified

Order By: Relevance

“…In our cohort five patients without any raised suspicion of malignancy were followed for less than 4 years, and an undiagnosed neoplastic disease cannot be excluded in these cases. Due to the well‐known risk of misclassifying IBM patients as polymyositis (Rose, 2013), and the relative paucity of inflammation in the more recent, pathologically defined, group, immune‐mediated necrotizing myopathy (Hoogendijk et al., 2004) (in this study classified as polymyositis), a particular effort was made to correctly identify and classify these patients.…”

Section: Discussionmentioning

confidence: 99%

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

et al. 2017

View full text Add to dashboard Cite

ObjectivesIdiopathic inflammatory myopathies (IIM) are often associated with other immune‐mediated diseases or malignancy. Some studies have reported a high frequency of celiac disease in IIM. The aim of this study was to investigate the prevalence of celiac disease, systemic inflammatory diseases, and malignancy in a cohort of IIM patients, and estimate the incidence of IIM in the county of Östergötland, Sweden.Material and MethodsWe reviewed medical records and analyzed sera from 106 patients, fulfilling pathological criteria of inflammatory myopathy, for the presence of IgA antibodies against endomysium and gliadin. Antibody‐positive patients were offered further investigation with small bowel biopsy or investigation for the presence of antibodies against antitissue transglutaminase (t‐TG). The patients were classified according to Bohan and Peter or Griggs criteria. The presence of celiac disease, systemic inflammatory, and malignant diseases was documented.ResultsFour of 88 patients classified as IIM (4.5%) had biopsy‐confirmed celiac disease, which is higher than the prevalence in the general population, detected with a similar screening procedure (0.53%). Thirty‐three patients (38%) had a systemic inflammatory disease and five (5.7%) a malignancy. The incidence of confirmed IIM in the county of Östergötland was 7.3 per million/year.ConclusionsThe results highlight the high frequency of associated inflammatory and malignant diseases and confirm an increased prevalence of celiac disease in IIM.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…New diagnostic criteria have since been proposed [1,2,23,24] but muscle biopsy remains the most sensitive and specific diagnostic tool, as well as the most common cause of misdiagnosis due to misinterpretation [25]. The inclusion of immunohistochemical staining for MHC-I has been recommended for cases of suspected IIM to increase the degree of diagnostic certainty [2,23].…”

Section: Discussionmentioning

confidence: 99%

“…Sets of diagnostic criteria for different types of IIM, based on a combination of clinical and pathological findings, have been proposed for use in clinical trials and research studies [1,2]. However, muscle biopsy is still the definitive diagnostic procedure in clinical practice and should ideally be performed before starting treatment [3].…”

Section: Introductionmentioning

confidence: 99%

An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies

Cruz

Luo

Miller

et al. 2014

Neuromuscular Disorders

View full text Add to dashboard Cite

MURDOCH RESEARCH REPOSITORYThis is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Abstract 1 Abstract 3 AbstractAlthough there have been several previous reports of immunohistochemical staining for MHC antigens in muscle biopsies, there appears to be a lack of consensus about its routine use in the diagnostic evaluation of biopsies from patients with suspected inflammatory myopathy. Positive MHC-I staining is nonspecific but is widely used as a marker for inflammatory myopathy, while the role of MHC-II staining is not clearly defined. We investigated the sensitivity and specificity of MHC-I and II immunostaining for the diagnosis of inflammatory myopathy in a large group of biopsies from a single reference laboratory. Positive staining for MHC-I was found to have a high sensitivity in biopsies from patients with inflammatory myopathy but a very low specificity, as it was also common in other non-inflammatory myopathies and neurogenic disorders.On the other hand, MHC-II positivity had a much higher specificity in all major subgroups of inflammatory myopathy, especially inclusion body myositis. The findings indicate that the combination of MHC-I and MHC-II staining results in a higher degree of specificity for the diagnosis of inflammatory myopathy and that in biopsies with inflammation, positive MHC-II staining strongly supports the diagnosis of an immunemediated myopathy. We recommend that immunohistochemical staining for both MHC-I and MHC-II should be included routinely in the diagnostic evaluation of muscle biopsies from patients with suspected inflammatory myopathy. However, as the sensitivity and interpretation of MHC staining may depend on the technique used, further studies are needed to compare procedures in different centres and develop standardised protocols.Abstract 4

show abstract

“…L'ensemble des dossiers clinico-biologiques et histologiques a ensuite été rediscuté. Les critères utilisés sont ceux s'appuyant sur les classifications de l'ENMC international workshop de 2003 [8] et une publication concernant plus spécifiquement les myosites de chevauchement [9]. Sur les 83 dossiers remplissant les critères sur la période étudiée, 22 ont été exclus (absence de suivi sur le CHU), trois par manque de données, 30 du fait d'un diagnostic final retenu discordant (principalement IBM mais aussi de manière plus anecdotique SLA, GVH musculaire…).…”

Section: Discussionunclassified

Diagnostic des myopathies inflammatoires au CHU de Bordeaux de 2012 à 2014

Duval

2017

Med Sci (Paris)

View full text Add to dashboard Cite

119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands

Cited by 792 publications

References 42 publications

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies

Diagnostic des myopathies inflammatoires au CHU de Bordeaux de 2012 à 2014

Contact Info

Product

Resources

About